Company & Sponsor Intelligence
Ruijin Hospital
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials8
Recruiting4
Completed0
Countries1
Therapeutic footprint
dementia_otherdepressionparkinsons
Indexed studies
NCT06946511Exploratory Study of the Effects of Peptide PMS-001 on Long-Delay Recall in Patients With Moderate to Severe Dementia
dementia_other · ChinaPHASE1, PHASE2
dementia_other · ChinaPHASE1, PHASE2
NCT07085195A Clinical Study of the Safety and Efficacy of Chemogenetics Therapy in the Treatment of Parkinson's Disease
parkinsons · ChinaEARLY_PHASE1
parkinsons · ChinaEARLY_PHASE1
NCT04528147Yi Jin Jing Tiger Roaring Speech Rehabilitation With Real-Time Feedback Technique for PD
parkinsons · ChinaNA
parkinsons · ChinaNA
NCT07553845A Multimodal Prospective Cohort Study of Parkinsonism
parkinsons · ChinaRECRUITING
parkinsons · ChinaRECRUITING
NCT03119051Shanghai Non-pharmacological Intervention of Mild Cognitive Impairment
dementia_other · ChinaNA
dementia_other · ChinaNA
NCT04137146SNS for Treatment of PD Gait Disorder
parkinsons · ChinaNA
parkinsons · ChinaNA
NCT07638813MSC-Exosome Therapy for Frontotemporal Dementia
dementia_other · PHASE1, PHASE2
dementia_other · PHASE1, PHASE2
NCT03347487DBS of the Habenula for Treatment- Resistant Major Depression
depression · ChinaNA
depression · ChinaNA
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →